1 Market Overview

• 1.1 Product Overview and Scope
• 1.2 Market Estimation Caveats and Base Year
• 1.3 Market Analysis by Type
  • 1.3.1 Overview: Global Sugemalimab Consumption Value by Type: 2021 Versus 2025 Versus 2032
  • 1.3.2 Intravenous Infusion
  • 1.3.3 Injection
• 1.4 Market Analysis by Combination Therapy
  • 1.4.1 Overview: Global Sugemalimab Consumption Value by Combination Therapy: 2021 Versus 2025 Versus 2032
  • 1.4.2 Combination with Chemotherapy
  • 1.4.3 Combination with Radiotherapy
• 1.5 Market Analysis by Sales Channels
  • 1.5.1 Overview: Global Sugemalimab Consumption Value by Sales Channels: 2021 Versus 2025 Versus 2032
  • 1.5.2 Hospitals
  • 1.5.3 Retail
  • 1.5.4 Online
• 1.6 Market Analysis by Application
  • 1.6.1 Overview: Global Sugemalimab Consumption Value by Application: 2021 Versus 2025 Versus 2032
  • 1.6.2 Non-Small Cell Lung Cancer
  • 1.6.3 Esophageal Squamous Cell Carcinoma
  • 1.6.4 Gastric And Gastroesophageal Junction Cancer
  • 1.6.5 Others
• 1.7 Global Sugemalimab Market Size & Forecast
  • 1.7.1 Global Sugemalimab Consumption Value (2021 & 2025 & 2032)
  • 1.7.2 Global Sugemalimab Sales Quantity (2021-2032)
  • 1.7.3 Global Sugemalimab Average Price (2021-2032)

2 Manufacturers Profiles

• 2.1 CStone Pharmaceuticals
  • 2.1.1 CStone Pharmaceuticals Details
  • 2.1.2 CStone Pharmaceuticals Major Business
  • 2.1.3 CStone Pharmaceuticals Sugemalimab Product and Services
  • 2.1.4 CStone Pharmaceuticals Sugemalimab Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
  • 2.1.5 CStone Pharmaceuticals Recent Developments/Updates
• 2.2 WuXi Biologics
  • 2.2.1 WuXi Biologics Details
  • 2.2.2 WuXi Biologics Major Business
  • 2.2.3 WuXi Biologics Sugemalimab Product and Services
  • 2.2.4 WuXi Biologics Sugemalimab Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
  • 2.2.5 WuXi Biologics Recent Developments/Updates

3 Competitive Environment: Sugemalimab by Manufacturer

• 3.1 Global Sugemalimab Sales Quantity by Manufacturer (2021-2026)
• 3.2 Global Sugemalimab Revenue by Manufacturer (2021-2026)
• 3.3 Global Sugemalimab Average Price by Manufacturer (2021-2026)
• 3.4 Market Share Analysis (2025)
  • 3.4.1 Producer Shipments of Sugemalimab by Manufacturer Revenue ($MM) and Market Share (%): 2025
  • 3.4.2 Top 3 Sugemalimab Manufacturer Market Share in 2025
  • 3.4.3 Top 6 Sugemalimab Manufacturer Market Share in 2025
• 3.5 Sugemalimab Market: Overall Company Footprint Analysis
  • 3.5.1 Sugemalimab Market: Region Footprint
  • 3.5.2 Sugemalimab Market: Company Product Type Footprint
  • 3.5.3 Sugemalimab Market: Company Product Application Footprint
• 3.6 New Market Entrants and Barriers to Market Entry
• 3.7 Mergers, Acquisition, Agreements, and Collaborations

4 Consumption Analysis by Region

• 4.1 Global Sugemalimab Market Size by Region
  • 4.1.1 Global Sugemalimab Sales Quantity by Region (2021-2032)
  • 4.1.2 Global Sugemalimab Consumption Value by Region (2021-2032)
  • 4.1.3 Global Sugemalimab Average Price by Region (2021-2032)
• 4.2 North America Sugemalimab Consumption Value (2021-2032)
• 4.3 Europe Sugemalimab Consumption Value (2021-2032)
• 4.4 Asia-Pacific Sugemalimab Consumption Value (2021-2032)
• 4.5 South America Sugemalimab Consumption Value (2021-2032)
• 4.6 Middle East & Africa Sugemalimab Consumption Value (2021-2032)

5 Market Segment by Type

• 5.1 Global Sugemalimab Sales Quantity by Type (2021-2032)
• 5.2 Global Sugemalimab Consumption Value by Type (2021-2032)
• 5.3 Global Sugemalimab Average Price by Type (2021-2032)

6 Market Segment by Application

• 6.1 Global Sugemalimab Sales Quantity by Application (2021-2032)
• 6.2 Global Sugemalimab Consumption Value by Application (2021-2032)
• 6.3 Global Sugemalimab Average Price by Application (2021-2032)

7 North America

• 7.1 North America Sugemalimab Sales Quantity by Type (2021-2032)
• 7.2 North America Sugemalimab Sales Quantity by Application (2021-2032)
• 7.3 North America Sugemalimab Market Size by Country
  • 7.3.1 North America Sugemalimab Sales Quantity by Country (2021-2032)
  • 7.3.2 North America Sugemalimab Consumption Value by Country (2021-2032)
  • 7.3.3 United States Market Size and Forecast (2021-2032)
  • 7.3.4 Canada Market Size and Forecast (2021-2032)
  • 7.3.5 Mexico Market Size and Forecast (2021-2032)

8 Europe

• 8.1 Europe Sugemalimab Sales Quantity by Type (2021-2032)
• 8.2 Europe Sugemalimab Sales Quantity by Application (2021-2032)
• 8.3 Europe Sugemalimab Market Size by Country
  • 8.3.1 Europe Sugemalimab Sales Quantity by Country (2021-2032)
  • 8.3.2 Europe Sugemalimab Consumption Value by Country (2021-2032)
  • 8.3.3 Germany Market Size and Forecast (2021-2032)
  • 8.3.4 France Market Size and Forecast (2021-2032)
  • 8.3.5 United Kingdom Market Size and Forecast (2021-2032)
  • 8.3.6 Russia Market Size and Forecast (2021-2032)
  • 8.3.7 Italy Market Size and Forecast (2021-2032)

9 Asia-Pacific

• 9.1 Asia-Pacific Sugemalimab Sales Quantity by Type (2021-2032)
• 9.2 Asia-Pacific Sugemalimab Sales Quantity by Application (2021-2032)
• 9.3 Asia-Pacific Sugemalimab Market Size by Region
  • 9.3.1 Asia-Pacific Sugemalimab Sales Quantity by Region (2021-2032)
  • 9.3.2 Asia-Pacific Sugemalimab Consumption Value by Region (2021-2032)
  • 9.3.3 China Market Size and Forecast (2021-2032)
  • 9.3.4 Japan Market Size and Forecast (2021-2032)
  • 9.3.5 South Korea Market Size and Forecast (2021-2032)
  • 9.3.6 India Market Size and Forecast (2021-2032)
  • 9.3.7 Southeast Asia Market Size and Forecast (2021-2032)
  • 9.3.8 Australia Market Size and Forecast (2021-2032)

10 South America

• 10.1 South America Sugemalimab Sales Quantity by Type (2021-2032)
• 10.2 South America Sugemalimab Sales Quantity by Application (2021-2032)
• 10.3 South America Sugemalimab Market Size by Country
  • 10.3.1 South America Sugemalimab Sales Quantity by Country (2021-2032)
  • 10.3.2 South America Sugemalimab Consumption Value by Country (2021-2032)
  • 10.3.3 Brazil Market Size and Forecast (2021-2032)
  • 10.3.4 Argentina Market Size and Forecast (2021-2032)

11 Middle East & Africa

• 11.1 Middle East & Africa Sugemalimab Sales Quantity by Type (2021-2032)
• 11.2 Middle East & Africa Sugemalimab Sales Quantity by Application (2021-2032)
• 11.3 Middle East & Africa Sugemalimab Market Size by Country
  • 11.3.1 Middle East & Africa Sugemalimab Sales Quantity by Country (2021-2032)
  • 11.3.2 Middle East & Africa Sugemalimab Consumption Value by Country (2021-2032)
  • 11.3.3 Turkey Market Size and Forecast (2021-2032)
  • 11.3.4 Egypt Market Size and Forecast (2021-2032)
  • 11.3.5 Saudi Arabia Market Size and Forecast (2021-2032)
  • 11.3.6 South Africa Market Size and Forecast (2021-2032)

12 Market Dynamics

• 12.1 Sugemalimab Market Drivers
• 12.2 Sugemalimab Market Restraints
• 12.3 Sugemalimab Trends Analysis
• 12.4 Porters Five Forces Analysis
  • 12.4.1 Threat of New Entrants
  • 12.4.2 Bargaining Power of Suppliers
  • 12.4.3 Bargaining Power of Buyers
  • 12.4.4 Threat of Substitutes
  • 12.4.5 Competitive Rivalry

13 Raw Material and Industry Chain

• 13.1 Raw Material of Sugemalimab and Key Manufacturers
• 13.2 Manufacturing Costs Percentage of Sugemalimab
• 13.3 Sugemalimab Production Process
• 13.4 Industry Value Chain Analysis

14 Shipments by Distribution Channel

• 14.1 Sales Channel
  • 14.1.1 Direct to End-User
  • 14.1.2 Distributors
• 14.2 Sugemalimab Typical Distributors
• 14.3 Sugemalimab Typical Customers

15 Research Findings and Conclusion

16 Appendix

• 16.1 Methodology
• 16.2 Research Process and Data Source

According to our (Global Info Research) latest study, the global Sugemalimab market size was valued at US$ 175 million in 2025 and is forecast to a readjusted size of US$ 840 million by 2032 with a CAGR of 11.7% during review period.
Sugemalimab is a fully human anti-PD-L1 monoclonal antibody. By selectively binding to PD-L1 on the surface of tumor cells, it blocks its interaction with the PD-1 receptor, relieves the immunosuppressive effect in the tumor microenvironment, and activates T-cell-mediated anti-tumor immune responses, thereby inhibiting tumor growth and eliminating tumor cells. The drug features high affinity, low immunogenicity and favorable safety profile. It is approved for the treatment of various malignant tumors including metastatic or locally advanced non-small cell lung cancer and esophageal squamous cell carcinoma. It can be used either as monotherapy or in combination with chemotherapy, radiotherapy and other regimens, providing an important immunotherapeutic option for patients with advanced tumors.In 2025, global Sugemalimab production reached approximately 280,000 vials.
Sugemalimab occupies a distinct competitive position in the global PD-L1 inhibitor market, balancing strong clinical differentiation with a strategic dual-market focus. As a fully human IgG4 antibody, it benefits from a favorable safety profile and low immunogenicity, supporting its adoption across both solid tumor indications and long-term maintenance therapies. Its unique advantage of covering both unresectable stage III and metastatic stage IV non-small cell lung cancer establishes broad utility in a high-prevalence disease area, while additional approvals in esophageal squamous cell carcinoma and gastric/gastroesophageal junction cancers expand its addressable patient population. In China, inclusion in the national medical insurance directory has driven significant market penetration by improving patient access and affordability, though it faces intense competition from numerous domestic PD-1/PD-L1 agents. Internationally, the drug has successfully entered major markets including the European Union and the United Kingdom, with partnerships expanding its commercial footprint to over 60 countries and regions, positioning it for gradual growth in global share. While challenged by pricing pressures and crowded therapeutic landscapes, its clinical versatility, international expansion, and established safety profile underpin its potential to capture sustained share in both emerging and established oncology immunotherapy markets.
This report is a detailed and comprehensive analysis for global Sugemalimab market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Sugemalimab market size and forecasts, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2021-2032
Global Sugemalimab market size and forecasts by region and country, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2021-2032
Global Sugemalimab market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2021-2032
Global Sugemalimab market shares of main players, shipments in revenue ($ Million), sales quantity (Units), and ASP (US$/Unit), 2021-2026
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Sugemalimab
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Sugemalimab market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include CStone Pharmaceuticals, WuXi Biologics, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market Segmentation
Sugemalimab market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
Intravenous Infusion
Injection
Market segment by Combination Therapy
Combination with Chemotherapy
Combination with Radiotherapy
Market segment by Sales Channels
Hospitals
Retail
Online
Market segment by Application
Non-Small Cell Lung Cancer
Esophageal Squamous Cell Carcinoma
Gastric And Gastroesophageal Junction Cancer
Others
Major players covered
CStone Pharmaceuticals
WuXi Biologics
Market segment by region, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Sugemalimab product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Sugemalimab, with price, sales quantity, revenue, and global market share of Sugemalimab from 2021 to 2026.
Chapter 3, the Sugemalimab competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Sugemalimab breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2021 to 2032.
Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2021 to 2032.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2021 to 2026.and Sugemalimab market forecast, by regions, by Type, and by Application, with sales and revenue, from 2027 to 2032.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Sugemalimab.
Chapter 14 and 15, to describe Sugemalimab sales channel, distributors, customers, research findings and conclusion.